Prognostic factors for efficacy of ipilimumab used after antiPD1 and/or BRAF+MEK inhibitors in melanoma patients: an Italian Melanoma Intergroup study

Home / Abstract / Prognostic factors for efficacy of ipilimumab used after antiPD1 and/or BRAF+MEK inhibitors in melanoma patients: an Italian Melanoma Intergroup study